* Biomerica Inc BMRA.OQ BMRA.O is expected to show a rise in
quarterly revenue when it reports results on October 13
(estimated).
* The Irvine, California-based company is expected to report a
66.1% increase in revenue to $1.9 million from $1.14 million a
year ago, according to the estimate from one analyst, based on
Refinitiv data.
* Refinitiv's mean analyst estimate for Biomerica Inc is for a
loss of 12 cents per share. For the same quarter last year, the
company reported a loss of 14 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 1 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 10.0% in the last three months.
* Wall Street's median 12-month price target for Biomerica Inc
is $12, about 44.1% above its last closing price of $6.71.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
May. 31 2021 -0.11 -0.12 Missed -10.4
Feb. 28 2021 -0.03 -0.08 -0.15 Missed -87.5
Nov. 30 2020 -0.10 -0.10 -0.13 Missed -33.3
Aug. 31 2020 -0.08 -0.08 -0.14 Missed -75
May. -0.07 -0.07 -0.04 Beat 40
31 2020
Feb. 29 2020 -0.07 -0.06 -0.09 Missed -38.5
Nov. 30 2019 -0.08 -0.05 Beat 37.5
Aug. 31 2019 -0.06 -0.06 -0.05 Beat 16.7
This summary was machine generated October 11 at 20:04 GMT. All
figures in US dollars unless otherwise stated